Clin2Atlas
AtlasDigestiveDigestive diseases

Appendicitis

4Curable or preventable in mostAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020251993 — Tazobactam approved (FDA)
1993: Drug approval — Tazobactam approved (FDA)

What's being tested now

2017: 2 trials started2019: 1 trials started2020: 3 trials started2021: 2 trials started2023: 6 trials started2024: 6 trials started2025: 18 trials started2026: 11 trials started2020202618

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 43 active Appendicitis trials on Clin2 →

Related

Paralytic ileus and intestinal obstructionInguinal, femoral, and abdominal herniaInflammatory bowel diseaseVascular intestinal disordersGallbladder and biliary diseasesPancreatitisOther digestive diseases

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.